Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Wang, Jia-Yang; Song, Yu; Peng, Jing; Luo, Hui

doi:10.1021/acsomega.0c02072

Cited by 11 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, an inhalable drug delivery system using NLCs loaded with doxorubicin, siRNA, and conjugated LHRH peptide showed better control of cancer cells than intravenous injections ( Table 3 ) [ 239 ]. Further, researchers found that NLC fabricated with doxorubicin and sorafenib can stimulate PD-1 expression, down-regulate Treg cells, activate effector T cells, and regenerate the immune response ( Table 4 ) while inhibiting esophagus tumors by bypassing the TME [ 240 ].…”

Section: Novel Nanocarriers Based Treatment Approachmentioning

confidence: 99%

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Sarma,

Akther,

Ahmad

et al. 2024

Molecules

View full text Add to dashboard Cite

Lung cancer has the lowest survival rate due to its late-stage diagnosis, poor prognosis, and intra-tumoral heterogeneity. These factors decrease the effectiveness of treatment. They release chemokines and cytokines from the tumor microenvironment (TME). To improve the effectiveness of treatment, researchers emphasize personalized adjuvant therapies along with conventional ones. Targeted chemotherapeutic drug delivery systems and specific pathway-blocking agents using nanocarriers are a few of them. This study explored the nanocarrier roles and strategies to improve the treatment profile’s effectiveness by striving for TME. A biofunctionalized nanocarrier stimulates biosystem interaction, cellular uptake, immune system escape, and vascular changes for penetration into the TME. Inorganic metal compounds scavenge reactive oxygen species (ROS) through their photothermal effect. Stroma, hypoxia, pH, and immunity-modulating agents conjugated or modified nanocarriers co-administered with pathway-blocking or condition-modulating agents can regulate extracellular matrix (ECM), Cancer-associated fibroblasts (CAF),Tyro3, Axl, and Mertk receptors (TAM) regulation, regulatory T-cell (Treg) inhibition, and myeloid-derived suppressor cells (MDSC) inhibition. Again, biomimetic conjugation or the surface modification of nanocarriers using ligands can enhance active targeting efficacy by bypassing the TME. A carrier system with biofunctionalized inorganic metal compounds and organic compound complex-loaded drugs is convenient for NSCLC-targeted therapy.

show abstract

Section: Novel Nanocarriers Based Treatment Approachmentioning

confidence: 99%

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Sarma,

Akther,

Ahmad

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…SOR-loaded NLC-A/B exhibited stronger antitumor activity than free SOR. Wang et al fabricated NLCs to co-deliver doxorubicin (DOX) and SOR 72 . With the combination of DOX-induced immunogenic cell death and SOR-mediated tumor microenvironment (TME) remodeling, the NPs showed strong anticancer benefits and immune response after treatment.…”

Section: Enhancing the Biocompatibility Of Sor With Npsmentioning

confidence: 99%

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the leading causes of cancer-related death worldwide. Advanced HCC displays strong resistance to chemotherapy, and traditional chemotherapy drugs do not achieve satisfactory therapeutic efficacy. Sorafenib is an oral kinase inhibitor that inhibits tumor cell proliferation and angiogenesis and induces cancer cell apoptosis. It also improves the survival rates of patients with advanced liver cancer. However, due to its poor solubility, fast metabolism, and low bioavailability, clinical applications of sorafenib have been substantially restricted. In recent years, various studies have been conducted on the use of nanoparticles to improve drug targeting and therapeutic efficacy in HCC. Moreover, nanoparticles have been extensively explored to improve the therapeutic efficacy of sorafenib, and a variety of nanoparticles, such as polymer, lipid, silica, and metal nanoparticles, have been developed for treating liver cancer. All these new technologies have improved the targeted treatment of HCC by sorafenib and promoted nanomedicines as treatments for HCC. This review provides an overview of hot topics in tumor nanoscience and the latest status of treatments for HCC. It further introduces the current research status of nanoparticle drug delivery systems for treatment of HCC with sorafenib.

show abstract

“…For this purpose, NLCs are being employed for targeting tumors. NLCs have been developed for the co-delivery of DOX and sorafenib (Sfn), where Sfn was expected to remodel the TME, consequently enhance the immunotherapy, which was then stimulated by DOX for successful esophagus cancer therapy ( Wang et al., 2020 ).…”

Section: Focus Of Current Lipid-based Theranostic Approachesmentioning

confidence: 99%

Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics

Bukhari

Zeth²,

Iftikhar³

et al. 2021

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

Nanotheranostics is an emerging frontier of personalized medicine research particularly for cancer, which is the second leading cause of death. Supramolecular aspects in theranostics are quite allured to achieve more regulation and controlled features. Supramolecular nanotheranostics architecture is focused on engineering of modular supramolecular assemblies benefitting from their mutable and stimuli-responsive properties which confer an ultimate potential for the fabrication of unified innovative nanomedicines with controlled features. Amalgamation of supramolecular approaches to nano-based features further equip the potential of designing novel approaches to overcome limitations seen by the conventional theranostic strategies, for curing even the lethal diseases and endowing personalized therapeutics with optimistic prognosis, endorsing their clinical translation. Among many potential nanocarriers for theranostics, lipid nanoparticles (LNPs) have shown various promising advances in theranostics and their formulation can be tailored for several applications. Despite the great advancement in cancer nanotheranostics, there are still many challenges that need to be highlighted to fill the literature gap. For this purpose, herein, we have presented a systematic overview on the subject and proposed LNPs as the potential material to manage cancer via non-invasive approaches by highlighting the use of supramolecular approaches to make them robust for cancer theranostics. We have concluded the review by entailing the future perspectives of lipid nanotheranostics towards clinical translation.

show abstract

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Cited by 11 publications

References 38 publications

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics

Contact Info

Product

Resources

About